Lubrizol’s Apinovex™ Polymer Honored with Prestigious Pharma Excipients Award at CPhI China 2025
Lubrizol Life Science Health’s Apinovex™ polymer has been awarded a prestigious Celebration Award in the Pharma Excipients Award category at CPhI China 2025, held in Shanghai from June 24–26. This recognition further solidifies Lubrizol’s role as an innovative leader in the development of pharmaceutical excipients that enhance drug formulation and delivery.
CPhI China is one of the most influential global events in the pharmaceutical industry, providing a platform for pharmaceutical professionals to connect, share insights, and showcase innovations across all areas of the supply chain. The annual event draws key stakeholders, including manufacturers, researchers, and service providers, from across the globe to collaborate on active pharmaceutical ingredients (APIs), contract development and manufacturing organizations (CDMOs), excipients, and more.
Apinovex polymer’s success at CPhI China 2025 adds to Lubrizol’s growing list of accolades in the excipient space. The polymer now stands alongside Apisolex™ polymer, another groundbreaking innovation by Lubrizol, which has already garnered multiple awards, including CPhI’s 2023 Global Innovation Award and the title of Grand Winner of the 2023 Annual Medicine Maker Innovation Award. The addition of Apinovex to this award-winning portfolio highlights Lubrizol’s sustained commitment to advancing pharmaceutical science through cutting-edge excipient technologies.
“We are excited to have received this additional recognition from CPhI following the earlier receipt of innovation awards for our novel injectable excipient, Apisolex™ polymer,” said Matt Finkelhor, Global Commercial Manager for Novel Polymers at Lubrizol. “These awards confirm that Lubrizol’s innovation is making a difference in drug delivery solutions that improve bioavailability and help bring more life-changing medications to market.”
Apinovex™ polymer was recognized for its exceptional potential to enhance the solubility and bioavailability of poorly water-soluble drugs, one of the most persistent challenges in modern drug development. By improving the performance and absorption of active pharmaceutical ingredients (APIs), Apinovex helps enable more effective treatments, especially for conditions requiring highly targeted or potent therapeutics.
The Importance of the Pharma Excipients Award
The Pharma Excipients Award is one of nine distinct categories within the broader CPhI Pharma Awards. This specific category acknowledges excipients that exhibit outstanding innovation, have significant market potential, and play a critical role in improving formulation performance or manufacturing efficiency. Products recognized in this category are often those that help raise the technical standards of the pharmaceutical industry and lead the way in shaping global trends.
The criteria for the award are rigorous and are intended to identify and celebrate companies that contribute meaningfully to the future of drug formulation. The award committee seeks out excipients that not only offer innovative functionality but also demonstrate scalability, compatibility with a wide range of APIs, and compliance with global regulatory requirements. Apinovex met these benchmarks and more, making it a standout candidate among numerous global submissions.
Lubrizol’s Continued Commitment to Innovation
As part of the Lubrizol Life Science Health business segment, Lubrizol’s Novel Polymers division has continued to push the boundaries of what’s possible in excipient technology. The company has built a strong reputation for pioneering functional polymers that solve long-standing formulation problems. With both Apinovex and Apisolex now earning international acclaim, Lubrizol is positioning itself as a leader in next-generation drug delivery solutions.
The back-to-back wins at CPhI and other major pharmaceutical innovation competitions demonstrate Lubrizol’s unique ability to address core industry challenges—particularly the formulation of poorly soluble or injectable compounds. These advances not only facilitate the development of new medications but also improve the safety, efficacy, and accessibility of treatments for patients worldwide.
